Just announced this morning... Cipher Pharmaceuticals Announces Extension of Distribution and Supply Agreement with Sun Pharmaceutical Industries Inc.
Royalty agreement granting Sun Pharmaceutical Industries Inc. exclusive right to market, sell and distribute Absorica, Absorica AG and Absorica LD in the U.S. extended through December 31, 2026
MISSISSAUGA, ON, March 10, 2022 /CNW/ -Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has entered into a second amended and restated distribution and supply agreement (the "Amendment") with Sun Pharmaceutical Industries, Inc. (Sun Pharma"), a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, India. Under the terms of the Amendment, Cipher and Sun Pharma have agreed to extend Sun Pharma's exclusive right to market, sell and distribute the isotrentinoin product portfolio, Absorica and Absorica AG in the United States ("U.S.") through December 31, 2026 and Absorica LD through December 31, 2024.
Under the terms of the Amendment, Cipher will continue to earn a royalty on U.S. net sales from Sun Pharma's isotrentinoin product portfolio, and will continue to be responsible for manufacturing the supplied product. The amendment extends the relationship from November 30, 2022 until December 31, 2026.
more in the pres release at the co web site